Generic name | Manufacturer | Indication(s) | Number of distinct studies required listed in the Qualify Notice | Number of distinct publications confirmed by company | Date drug received Notice of Compliance with conditions (year-month-day) | Date drug fulfilled conditions (year-month-day) |
Abacavir | GlaxoSmithKline | HIV/AIDS | 3 | 3 | 1999-04-06 | 2001-09-01 |
Alteplase | Hoffman-LaRoche | Stroke | 2 | 2 | 1999-02-16 | 2005-01-26 |
Anastrozole | AstraZeneca | Breast cancer | 3 | 1 | 2004-06-20 | 2008-12-02 |
Bortezomib | Janssen | Relapsed multiple myeloma | 1 | 1 | 2005-01-27 | 2007-09-11 |
Capecitabine | Hoffman-LaRoche | Bowel cancer | 1 | 1 | 2005-12-07 | 2008-10-23 |
Crizotinib | Pfizer | Lung cancer | 2 | 2 | 2012-04-25 | 2015-11-18 |
Darunavir | Janssen | HIV/AIDS | 2 | 2 | 2006-07-28 | 2009-02-11 |
Dasatinib | Bristol-Myers Squibb | Chronic myeloid leukaemia—two indications | 3 | 3 | 2007-03-26 2011-07-19 | 2009-11-19 2015-11-26 |
Eculizumab | Alexion | Paroxysmal nocturnal haemoglobinuria | 2 | 2 | 2013-03-01 | 2015-06-30 |
Exemestane | Pfizer | Breast cancer | 3 | 3 | 2006-05-12 | 2008-08-06 |
Gefitinib | AstraZeneca | Lung cancer | 4 | 3 (two studies published in one article) | 2003-12-17 | 2009-12-18 |
Lenalidomide | Celgene | Myelodysplastic syndromes | 1 | 1 | 2008-01-07 | 2013-06-06 |
Levodopa/carbidopa | AbbVie | Parkinson’s disease | 2 | 2 | 2007-03-01 | 2014-03-12 |
Pregabalin | Pfizer | Central neuropathic pain | 1 | 1 | 2007-11-09 | 2010-06-29 |
Recombinant factor VIIa | Novo Nordisk | Clotting disorders | 1 | 1 | 1999-02-12 | 2005-06-19 |
Simeprevir | Janssen | HIV/AIDS | 2 | 2 | 2015-01-30 | 2016-11-29 |
Sorafenib | Bayer | Kidney cancer | 3 | 2 (two studies published in one article) | 2006-07-28 | 2009-06-12 |
Sunitinib | Pfizer | Renal cancer—two indications | 3 | 3 | 2006-08-17 2008-05-01 | 2010-04-23 2010-04-23 |
Zanamivir | GlaxoSmithKline | Influenza | 1 | 1 | 1999-08-26 | 2003-08-26 |